---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000834946.md"
description: "📢 𝗝𝗨𝗦𝗧 𝗜𝗡: Novo Nordisk Raises 2026 Outlook on Stronger GLP-1 Sales Expectations - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US) 👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:➤  𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸 raised its full-year 𝟮𝟬𝟮𝟲 adjusted guidance.➤  Higher outlook reflects stronger expected 𝗚𝗟𝗣-𝟭 product sales.➤  Adjusted sales guidance improved to 𝟬% 𝘁𝗼 -𝟲% at CER.➤  Previous adjusted sales outlook was -𝟰% 𝘁𝗼 -𝟭𝟮% at CER.➤  Adjusted operating profit guidance improved to 𝟬% 𝘁𝗼 -𝟲% at CER.➤  𝗤𝟮 adjusted sales reached 𝗗𝗞𝗞 𝟳𝟴,𝟰𝟴𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻, up 𝟳% at CER.➤  𝗤𝟮 adjusted operating profit totaled 𝗗𝗞𝗞 𝟯𝟯,𝟯𝟴𝟵 𝗺𝗶𝗹𝗹𝗶𝗼𝗻, up 𝟭𝟭% at CER.➤  Results exclude one-time impacts from the U.S. 𝟯𝟰𝟬𝗕 𝗗𝗿𝘂𝗴 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗣𝗿𝗼𝗴𝗿𝗮𝗺.➤  𝗤𝟮 included 𝗗𝗞𝗞 𝟲.𝟯 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 in non-cash impairment charges.👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀:➤  Improved guidance signals stronger-than-expected demand for 𝗚𝗟𝗣-𝟭 therapies.➤  Higher outlook may strengthen investor confidence in Novo Nordisk's earnings trajectory.➤  Excluding one-time items provides a clearer view of underlying operating performance."
datetime: "2026-08-04T16:46:43.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000834946.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000834946.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000834946.md)
author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)"
generator: "portal-rs"
---

# 📢 𝗝𝗨𝗦𝗧 𝗜𝗡: Novo Nordisk Raises 2026 Outlook on Str…


### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**